Congenital disorders associated with platelet dysfunctions.

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Genetic defects in the megakaryocyte lineage lead to various bleeding syndromes.
• Platelet dysfunction impairs hemostasis, causing mucocutaneous bleeding and issues with trauma response.
• Key defects involve adhesion (Bernard-Soulier syndrome), aggregation (Glanzmann thrombasthenia), and signaling pathways.

Purpose of the Study:

• To review genetic defects affecting platelet function and production.
• To highlight the molecular basis of inherited bleeding disorders.
• To discuss current and emerging therapeutic strategies.

Main Methods:

• Review of literature on genetic platelet disorders.
• Analysis of molecular mechanisms underlying platelet dysfunction.
• Summary of clinical manifestations and treatment approaches.

Main Results:

• Defects in glycoprotein mediators (GPIb-IX-V, alphaIIbbeta3), P2Y(12)ADP receptor, and signaling pathways cause impaired adhesion and aggregation.
• Disorders of secretion, ATP production, and procoagulant activity also contribute to bleeding.
• Familial thrombocytopenia and MYH9-related diseases demonstrate issues with platelet production and morphology.

Conclusions:

• Genetic platelet disorders range from mild to severe, impacting hemostasis through various molecular defects.
• Current treatments include platelet transfusion, desmopressin, and supportive therapies like rFVIIa.
• Future therapies may involve TPO analogues, stem cell transplantation, and gene therapy for severe cases.